Inclusion Criteria:

- Patients must be platinum resistant

- Patients will be included in the study based on the following criteria:

- No prior anthracycline use

- PS less or equal 2

- Lab values within certain limits (ANC greater 1000, platelets greater 100,000;
ALT, AST 2 time ULN, creatinine less 2.0)

- No more than 3 prior chemotherapy regimens, only 2 of which can have included
platinum-containing regimens

- Use of effective means of contraception in subjects of child-bearing potential

Exclusion Criteria:

1. Disease-Specific Exclusions:

- Evidence of complete or partial bowel obstruction

- Need for IV hydration or TPN

- Greater 2 prior abdominal surgeries

- History of gastrointestinal perforation

- Gastrointestinal perforation due to any other cause within the last 6 months

2. General Medical Exclusions:

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 12 weeks

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
Avastin cancer study

3. Avastin-Specific Exclusions

- Inadequately controlled hypertension (defined as systolic blood pressure 150
and/or diastolic blood pressure greater 100 mmHg on antihypertensive
medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Grade II or greater congestive heart failure
(see Appendix E)

- History of myocardial infarction or unstable angina within 6 months prior to
study enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Known CNS disease

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28
days prior to study enrollment or anticipation of need for major surgical
procedure during the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, or intra-abdominal abscess within 6 months prior
to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening as demonstrated by either:

- Urine protein:creatinine (UPC) ratio 1.0 at screening OR

- Urine dipstick for proteinuria greater or equal 2plus (patients discovered
to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline
should undergo a 24 hour urine collection and must demonstrate less or
equal 1g of protein in 24 hours to be eligible)

- Known hypersensitivity to any component of Avastin

- Pregnant (positive pregnancy test) or lactating. No effective means of
contraception (men and women) in subjects of child-bearing potential